Cellceutix, Beth Israel Deaconess deal

Cellceutix and the center partnered to research Cellceutix's Kevetrin to treat melanoma and renal cell carcinoma (RCC). Kevetrin is a small molecule protein kinase B (PKB; PKBA; AKT; AKT1) inhibitor that also acts as an alkylating agent and leukotriene B4 (LTB4) inhibitor with anti-angiogenic properties in preclinical development for cancer. Cellceutix said funding for the studies would come from other parties and that the partnership would be independent of the biotech's clinical development plan. The medical center is interested in nuclear and/or mitochondrial pro-apoptotic function of p53 in melanoma and RCC. Details were not disclosed. ...